"The drug, called olaparib – a type of treatment called a PARP inhibitor – will be given after chemotherapy to patients with non-small cell lung cancer (NSCLC) to see if it delays the growth of their tumour.
"The phase II trial will recruit over 100 people with advanced non-small cell lung cancer at 25 hospitals around the UK. It is funded by Cancer Research UK and AstraZeneca through a National Cancer Research Network initiative and is being co-ordinated by Cancer Research UK’s Wales Cancer Trials Unit at Cardiff University and Velindre NHS Trust in Cardiff."
Editor's Note: More and more, scientists are finding that different types of cancer (breast and lung cancer, for instance) can sometimes have similarities, meaning that a treatment that works for one type might also work for another type. This study is exploring once such treatment.